Ferdinando D’Amico | Medicine and Health Sciences | Best Researcher Award

Ferdinando D’Amico | Medicine and Health Sciences | Best Researcher Award

Dr Ferdinando D’Amico, IRCCS San Raffaele Hospital, Italy

Dr. Ferdinando D’Amico is a distinguished gastroenterologist at IRCCS San Raffaele Hospital in Milan, Italy, with expertise in gastroenterology and endoscopy. 🎓 He completed his residency in Gastroenterology/Digestive Diseases and earned his PhD at Hunimed University, focusing on histology in inflammatory bowel diseases. His academic journey includes a degree in Medicine and Surgery from “Cattolica del Sacro Cuore” University, where he researched intestinal permeability and atherosclerosis. 🏥 His training included internships in gastroenterology and cardiology at “Agostino Gemelli” Hospital in Rome. Dr. D’Amico is proficient in English and French, and skilled in digital communication. 🌍🔬

Publication profile

Scopus

Education 

🎓 From 2003 to 2008, attended Classical High School, graduating with highest honours. From 2009 to 2015, pursued a Degree in Medicine and Surgery at “Cattolica del Sacro Cuore” University, Rome, also graduating with highest honours. 🏆 The dissertation, titled “Alterations in Intestinal Permeability and Inflammation: A Novel Potential Mechanism of Atherosclerosis,” was supervised by Professor Filippo Crea. 📜 Currently registered with the Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri di Caserta, registration number 7593. 🩺

Experience

From November 1, 2016, to November 2, 2020, [Name] completed their residency in Gastroenterology/Digestive System Diseases at Hunimed University in Pieve Emanuele, Italy, graduating with highest honors. They then pursued a Ph.D. at the same institution, focusing on “The Role of Histology in Inflammatory Bowel Diseases,” under the guidance of Prof. Silvio Danese. From January 1, 2021, to February 9, 2024, they worked as a Gastroenterologist at the IRCCS San Raffaele Hospital in Milan, Italy, in the Gastroenterology and Endoscopy Unit, also directed by Prof. Silvio Danese. 🏥📚🩺

Research focus

Based on the provided publications, the research focus appears to be on inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis. The studies address various aspects such as comparing treatments (e.g., tofacitinib vs. ustekinumab), assessing remission through non-invasive methods, and evaluating regulatory guidance for JAK inhibitors. The research also explores the use of biologics and other therapies in managing IBD, including switching between different treatment forms. This indicates a strong emphasis on optimizing treatment strategies and improving patient outcomes in IBD. 🌟📚💊

Publication top notes

Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn’s disease: a prospective cohort study

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

The role of filgotinib in ulcerative colitis and Crohn’s disease

A new national survey of centers for cognitive disorders and dementias in Italy

An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn’s disease

MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations

Advancing transmural remission as a treatment target in Crohn’s disease: The future of tight-control strategy?

Noninvasive Assessment of Postoperative Disease Recurrence in Crohn’s Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease

 

 

Matheus Sewastjanow-Silva | Health Sciences | Best Researcher Award

Dr. Matheus Sewastjanow-Silva | Health Sciences | Best Researcher Award

Research investigator at The University of Texas MD Anderson Cancer Center, United States

Matheus Sewastjanow da Silva is a Research Investigator at the University of Texas MD Anderson Cancer Center, focusing on clinical studies databases and manuscript analysis. Previously, he worked in Jaffer Ajani’s lab and was a General Practitioner in Brazil, providing emergency and outpatient care. He holds an M.D. from the Federal University of Minas Gerais (UFMG), with internships in various medical specialties at institutions like A.C. Camargo Cancer Center and Jackson Memorial Hospital. Matheus has extensive research experience in surgery and immunology and has actively participated in volunteer medical campaigns and student leadership roles.

Professional Profiles:

🎓 Education

Matheus Sewastjanow da Silva, M.D., earned his Doctor of Medicine (M.D.) from the Federal University of Minas Gerais School of Medicine in Brazil (2012-2018). His education included additional internships at prominent institutions. He completed a rural outpatient care internship in Esmeraldas, Brazil, and specialized training in Otolaryngology – Head & Neck Surgery at A.C. Camargo Cancer Center, São Paulo, and in Skin, Head & Neck, and Micro/Reconstructive Surgery at Barretos Cancer Hospital. Dr. da Silva also trained in Transplant Surgery and Mohs Micrographic Surgery at the University of Miami. His education was supplemented by various courses, including Pediatric Advanced Life Support (PALS), Advanced Cardiovascular Life Support (ACLS), clinical emergencies, and advanced dermatological surgery. Additionally, he completed courses in clinical therapeutics, psychosomatic diseases, primary immunodeficiencies, and languages (French and Latin). This diverse and rigorous training underscores his commitment to comprehensive medical education and patient care.

Professional Experience

Dr. Matheus Sewastjanow da Silva is currently a Research Investigator in Shirley Su’s research group at the Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center (07/2024-present). His responsibilities include managing clinical studies/trials databases, analyzing and writing manuscripts, and utilizing tools such as RedCap, Epic/SlicerDicer, Foundry, Universe, and Prometheus. Previously, he worked as a Research Investigator in Jaffer Ajani’s lab at the Department of Gastrointestinal Medical Oncology at the same institution (09/2020-06/2024), where he handled clinical samples, patient enrollment, and various laboratory techniques. Before his roles at MD Anderson, Dr. da Silva served as a Physician/General Practitioner in multiple clinics and hospitals across Brazil, providing both outpatient and emergency care, including treating COVID-19 patients. His roles included positions at Nazare Public Family Medicine Clinic, Private Hospital Santa Helena, Public Hospital Vinte e Cinco de Maio, and several Public Emergency Care Centers. Additionally, he gained research experience as an Assistant at the Federal University of Minas Gerais, contributing to studies in General Surgery and Biochemistry, Cellular, and Molecular Immunology.

Research Interest

Dr. Matheus Sewastjanow da Silva is deeply interested in clinical and translational research, focusing on head and neck surgery, gastrointestinal oncology, and emergency medicine. His current research in Shirley Su’s group at MD Anderson Cancer Center involves filling and maintaining clinical studies and trials databases, as well as analyzing and writing manuscripts. He has extensive experience with advanced tools like RedCap, Epic/SlicerDicer, Foundry, Universe, and Prometheus. Dr. da Silva’s previous research in Jaffer Ajani’s lab involved the collection and processing of clinical samples, patient enrollment, DNA/RNA extraction, cell culture, and various molecular biology techniques such as qPCR, Western Blotting, and viral transfections. His research interests extend to the development of novel therapeutic strategies, biomarker discovery, and improving patient outcomes in oncology. Additionally, he is passionate about medical education and the integration of research findings into clinical practice to enhance healthcare delivery.

Award and Honors

Dr. Matheus Sewastjanow da Silva has been recognized for his outstanding contributions to medicine and research through numerous awards and honors. His notable achievements include multiple grant awards and scholarships from esteemed organizations such as the National Council for Scientific and Technological Development (CNPq) and the Research Support Foundation of the State of Minas Gerais (FAPEMIG). Throughout his academic and professional journey, Dr. da Silva has demonstrated exceptional commitment and excellence in his field, earning accolades for his research work, particularly in biochemistry, cellular and molecular immunology, and oncology. His dedication to advancing medical knowledge and improving patient care has been consistently acknowledged, solidifying his reputation as a distinguished physician and researcher in the medical community.

Research Experience 🔬

  • Research Assistant at UFMG General Surgery Laboratory – Andy Petroianu M.D., PhD (07/2015 – 12/2017)
    Roles: Research design, patient consenting, data collection/analysis, database management, manuscript preparation.
  • Research Assistant at UFMG Biochemistry, Cellular and Molecular Immunology Laboratory II – Dawidson Assis Gomes, Msc, PhD (10/2012 – 07/2015)
    Grant Awards: CNPq, FAPEMIG
    Roles: Lab preparations, rodent handling, tissue processing, DNA/RNA extraction, immunohistochemistry, PCR, ELISA, Western Blotting, flow cytometry, data analysis, manuscript preparation.

Research Skills

Proficient in managing clinical studies and trials databases using RedCap, Epic/SlicerDicer, Foundry, Universe, and Prometheus, I have extensive experience in collecting, processing, and managing clinical samples, including blood, ascites, and tissue. My molecular techniques expertise encompasses DNA/RNA extraction, qPCR, Western Blotting, viral transfections, and immunohistochemistry. Additionally, I am skilled in cell isolation, culture, and viral transfections. I have significant experience in rodent handling and conducting mouse studies. Competent in statistical analysis and data interpretation using various software tools, I am also proficient in writing and reviewing abstracts, articles, manuscripts, posters, and slide presentations. My laboratory skills include preparing buffers, tissue staining, cryostat tissue sectioning, PCR, ELISA, flow cytometry, and cell culture.

Publications

  • SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel
    • Authors: Yamashita, K., Sewastjanow-Silva, M., Yoshimura, K., …, Wang, L., Ajani, J.A.
    • Year: 2024
  • Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study
    • Authors: Sewastjanow-Silva, M., Xiao, L., Gonzalez, G.N., …, Ajani, J.A., Murphy, M.B.
    • Year: 2024
  • Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target
    • Authors: Rogers, J.E., Yamashita, K., Sewastjanow-Silva, M., …, Waters, R.E., Ajani, J.
    • Year: 2023
    • Citations: 2
  • Challenges and Prospects of Patient-Derived Xenografts for Cancer Research
    • Authors: Jin, J., Yoshimura, K., Sewastjanow-Silva, M., Song, S., Ajani, J.A.
    • Year: 2023
    • Citations: 12
  • Evolution of Immune and Stromal Cell States and Ecotypes during Gastric Adenocarcinoma Progression
    • Authors: Wang, R., Song, S., Qin, J., …, Ajani, J.A., Wang, L.
    • Year: 2023
    • Citations: 14
  • Epithelial SOX9 Drives Progression and Metastases of Gastric Adenocarcinoma by Promoting Immunosuppressive Tumour Microenvironment
    • Authors: Fan, Y., Li, Y., Yao, X., …, Ajani, J.A., Song, S.
    • Year: 2023
    • Citations: 24
  • A New Intronic Quantitative PCR Method Led to the Discovery of Transformation from Human Ascites to Murine Malignancy in a Mouse Model
    • Authors: Jin, J., Huo, L., Fan, Y., …, Song, S., Ajani, J.A.
    • Year: 2023
    • Citations: 1
  • Nivolumab Combination Therapy as First-Line Treatments for Unresectable, Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    • Authors: Rogers, J.E., Yamashita, K., Sewastjanow-Silva, M., …, Waters, R., Ajani, J.A.
    • Year: 2023
    • Citations: 1
  • GRK3 Is a Poor Prognosticator and Serves as a Therapeutic Target in Advanced Gastric Adenocarcinoma
    • Authors: Li, Y., Fan, Y., Xu, J., …, Song, S., Ajani, J.A.
    • Year: 2022
    • Citations: 3
  • Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors
    • Authors: Rogers, J.E., Yamashita, K., Sewastjanow Silva, M., Ajani, J.A.
    • Year: 2022